Skip to main content
logo
Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.520
+0.050 (3.40%)
At close: Jan 22, 2026, 4:00 PM EST
1.510
-0.010 (-0.66%)
After-hours: Jan 22, 2026, 7:28 PM EST

Autolus Therapeutics Revenue

Autolus Therapeutics had revenue of $21.19M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $51.13M, up 406.67% year-over-year. In the year 2024, Autolus Therapeutics had annual revenue of $10.12M with 496.00% growth.

Revenue (ttm)
$51.13M
Revenue Growth
+406.67%
P/S Ratio
7.91
Revenue / Employee
$78,658
Employees
650
Market Cap
404.54M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202410.12M8.42M496.00%
Dec 31, 20231.70M-4.66M-73.30%
Dec 31, 20226.36M4.03M172.96%
Dec 31, 20212.33M615.00K35.86%
Dec 31, 20201.72M-1.19M-41.02%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Sep 30, 2018 Pro Pro Pro
Sep 30, 2017 Pro Pro Pro
Sep 30, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Entrada Therapeutics61.52M
Assembly Biosciences37.19M
Lineage Cell Therapeutics10.82M
Immutep3.31M
Allogene Therapeutics22.00K
vTv Therapeutics17.00K
Revenue Rankings

AUTL News

More News